Lower GI Series Market Share

Lower GI Series Market Overview 

Lower GI Series Market Size was valued at USD 248.46 Billion in 2023. The Global Lower GI Series industry is projected to grow from USD 268.11 Billion in 2024 to USD 478.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.15% during the forecast period (2024 - 2032).

Lower GI series is a lower gastrointestinal series or barium enema; it is one of the medical procedure, which helps in diagnosis of diseases and abnormalities related to human large intestine and rectum. Moreover, major companies are focusing on investment in R&D to introduce efficient methods as well as innovative devices since they are under constant pressure to provide new and cost-effective methods.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60-70 million people are affected by either major or minor GIT diseases in America. The number is continuously increasing due to poor diet and increasing aging population. The lower GI series market is driven majorly due to increasing prevalence of GI diseases, gastric cancer, and changing lifestyle. Additionally, developing technologies, increasing cost-effective methods, and the government’s support for research have boosted the growth of this market. However, availability of alternative therapies may hamper the growth of the market during the review period.

Lower GI Series Market Segmentation                                           

The lower GI series market is segmented on the basis of by applications, types of tests, and end user.

On the basis of applications, it is segmented into gastroenteritis, colon polyps, tumor, strictures crohn's disease, ulcerative colitis, and others.

On the basis of types of test, it is segmented into double-contrast test and single-contrast test.

On the basis of end users, this market is segmented into hospitals, clinics, and laboratories.

Regional Analysis of the Lower GI Series Market

On the regional basis, the market is segmented into the America, Europe, Asia Pacific, and the Middle East & Africa. The America owns a significant share in the global market as a result of huge investment in research and development in the healthcare sector and its strong economic conditions for research and development. Increasing patient base and geriatric population to boost the growth of the Lower GI Series Market. 

Europe is the second largest market followed by Asia Pacific on account of increasing technological improvements. The technological improvements will result in higher efficiency and accuracy for diagnosis. Asia Pacific is the fastest growing market due to increasing prevalence of communicable diseases in this region. India and China have started investing in research and development of healthcare sector, which will boost the Lower GI Series Market growth of this region.

Key Players in the Lower GI Series Market  

Some of the key players in Lower GI Series Market are: 

• Eisai (US)


• Cadila Pharmaceuticals


• PeaceHealth


• Purdue Pharma L.P.


• Alfa Wassermann


• NOVADAQ


• Mount Sinai Beth Israel


• AstraZeneca


• Ironwood Pharmaceuticals Inc.  

Intended Audience

• Manufacturing industries


• Pharmaceutical industry


• Biotechnology companies


• Research and development (R&D) companies


• Government research laboratories


• Medical research institutes